With 71003.0 shares changed hands, the volume of the stock remained lighter than its average volume of 0.11 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.57 whereas the lowest price it dropped to was $1.43. The 52-week range on CAMP shows that it touched its highest point at $12.30 and its lowest point at $1.30 during that stretch. It currently has a 1-year price target of $14.33.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CAMP was down-trending over the past week, with a drop of -1.94%, but this was down by -6.75% over a month. Three-month performance dropped to -23.23% while six-month performance fell -69.04%. A look at the trailing 12-month EPS for CAMP yields -2.57 with Next year EPS estimates of -1.94. For the next quarter, that number is -0.66. This implies an EPS growth rate of 78.64% for this year and 17.54% for next year.
Float and Shares Shorts:
At present, 20.16 million CAMP shares are outstanding with a float of 2.64 million shares on hand for trading. On 2025-08-15, short shares totaled 0.22 million, which was 109.99999999999999 higher than short shares on 1752537600. In addition to Mr. Joshua Mandel-Brehm as the firm’s CEO, President & Director, Dr. Richard A. Young Ph.D. serves as its Founder & Independent Director.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, CAMP reported revenue of $1497000.0 and operating income of -$13028000.0. The EBITDA in the recently reported quarter was -$12598000.0 and diluted EPS was -$0.62.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CAMP since 4 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CAMP analysts setting a high price target of 21.65 and a low target of 8.0, the average target price over the next 12 months is 16.53. Based on these targets, CAMP could surge 1324.34% to reach the target high and rise by 426.32% to reach the target low. Reaching the average price target will result in a growth of 987.5% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$6.22663 being high and -$10.36659 being low. For CAMP, this leads to a yearly average estimate of -$8.33. The surprise factor in the prior quarter was -$0.7. Based on analyst estimates, the high estimate for the next quarter is -$0.32 and the low estimate is -$0.72. The average estimate for the next quarter is thus -$0.51.